Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany

Affiliations

• ¹ German Central Committee against Tuberculosis (DZK), Berlin, Germany [email protected].
• ² German Central Committee against Tuberculosis (DZK), Berlin, Germany.
• ³ Lung Hospital Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.
• ⁴ Division of Infectious Diseases, Department of Medicine II, Medical Center, University of Freiburg, Freiburg, Germany.
• ⁵ Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
• ⁶ German Center for Infection Research (DZIF), TTU-TB, Borstel, Germany.
• ⁷ Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
• ⁸ Asklepios Fachklinik Gauting, Gauting, Germany.
• ⁹ Lungenärzte am Rundfunkplatz, Munich, Germany.
• ¹⁰ Department I of Internal Medicine, Faculty of Medicine and University of Cologne, University of Cologne, Cologne, Germany.
• ¹¹ Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University of Cologne, University of Cologne, Cologne, Germany.
• ¹² German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
• ¹³ Department of Pulmonology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
• ¹⁴ Department of Human, Biological and Translational Medical Sciences, University of Namibia, School of Medicine, Windhoek, Namibia.
• ¹⁵ Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.
• ¹⁶ Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.